# STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH

> **NCT00277875** · PHASE2 · COMPLETED · sponsor: **Synvista Therapeutics, Inc** · enrollment: 25 (—)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** ALT-711 (alagebrium chloride)

## Key facts

- **NCT ID:** NCT00277875
- **Lead sponsor:** Synvista Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2004-12
- **Final completion:** 2006-01
- **Target enrollment:** 25 (—)
- **Last updated:** 2009-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00277875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00277875, "STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00277875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*